These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

183 related articles for article (PubMed ID: 28328525)

  • 1. Moving sum of number of positive patient result as a quality control tool.
    Liu J; Tan CH; Badrick T; Loh TP
    Clin Chem Lab Med; 2017 Oct; 55(11):1709-1714. PubMed ID: 28328525
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Moving standard deviation and moving sum of outliers as quality tools for monitoring analytical precision.
    Liu J; Tan CH; Badrick T; Loh TP
    Clin Biochem; 2018 Feb; 52():112-116. PubMed ID: 29107011
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Patient-based quality control for glucometers: using the moving sum of positive patient results and moving average.
    Lim CY; Badrick T; Loh TP
    Biochem Med (Zagreb); 2020 Jun; 30(2):020709. PubMed ID: 32550817
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Implementation and application of moving average as continuous analytical quality control instrument demonstrated for 24 routine chemistry assays.
    Rossum HHV; Kemperman H
    Clin Chem Lab Med; 2017 Jul; 55(8):1142-1151. PubMed ID: 28076303
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Moving Rate of Positive Patient Results as a Quality Control Tool for High-Sensitivity Cardiac Troponin T Assays.
    Li T; Cao S; Wang Y; Xiong Y; He Y; Ke P; Huang X
    Ann Lab Med; 2021 Jan; 41(1):51-59. PubMed ID: 32829579
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A primer on patient-based quality control techniques.
    Badrick T; Cervinski M; Loh TP
    Clin Biochem; 2019 Feb; 64():1-5. PubMed ID: 30550876
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Design and implementation of quality control plans that integrate moving average and internal quality control: incorporating the best of both worlds.
    van Rossum HH; van den Broek D
    Clin Chem Lab Med; 2019 Aug; 57(9):1329-1338. PubMed ID: 30903753
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Between and within calibration variation: implications for internal quality control rules.
    Lim CY; Lee JJS; Choy KW; Badrick T; Markus C; Loh TP
    Pathology; 2023 Jun; 55(4):525-530. PubMed ID: 36894352
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Ten-Month Evaluation of the Routine Application of Patient Moving Average for Real-Time Quality Control in a Hospital Setting.
    van Rossum HH; van den Broek D
    J Appl Lab Med; 2020 Nov; 5(6):1184-1193. PubMed ID: 32533149
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Spurious elevation of serum PSA after curative treatment for prostate cancer: clinical consequences and the role of heterophilic antibodies.
    Anderson CB; Pyle AL; Woodworth A; Cookson MS; Smith JA; Barocas DA
    Prostate Cancer Prostatic Dis; 2012 Jun; 15(2):182-8. PubMed ID: 22105412
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Selecting multi-rule quality control procedures based on patient risk.
    Bayat H
    Clin Chem Lab Med; 2017 Oct; 55(11):1702-1708. PubMed ID: 28236626
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Should I repeat my 1:2s QC rejection?
    Parvin CA; Kuchipudi L; Yundt-Pacheco JC
    Clin Chem; 2012 May; 58(5):925-9. PubMed ID: 22357876
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Steady state errors and risk of a QC strategy.
    Mackay MA; Badrick TC
    Clin Biochem; 2019 Feb; 64():37-43. PubMed ID: 30552866
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Digital rectal examination is no longer necessary in the routine follow-up of men with undetectable prostate specific antigen after radical prostatectomy: the implications for follow-up.
    Chaplin BJ; Wildhagen MF; Schroder FH; Kirkels WJ; Bangma CH
    Eur Urol; 2005 Dec; 48(6):906-10. PubMed ID: 16126322
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Prostate-specific antigen: bias and molarity of commercial assays for PSA in use in England.
    Roddam AW; Rimmer J; Nickerson C; Ward AM;
    Ann Clin Biochem; 2006 Jan; 43(Pt 1):35-48. PubMed ID: 16390608
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Performance evaluation and planning for patient-based quality control procedures.
    Ye JJ; Ingels SC; Parvin CA
    Am J Clin Pathol; 2000 Feb; 113(2):240-8. PubMed ID: 10664626
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A method for optimization and validation of moving average as continuous analytical quality control instrument demonstrated for creatinine.
    van Rossum HH; Kemperman H
    Clin Chim Acta; 2016 Jun; 457():1-7. PubMed ID: 27012515
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Detection of prostate cancer relapse with prostate specific antigen monitoring at levels of 0.001 to 0.1 microG./L.
    Yu H; Diamandis EP; Wong PY; Nam R; Trachtenberg J
    J Urol; 1997 Mar; 157(3):913-8. PubMed ID: 9072598
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Moving average quality control: principles, practical application and future perspectives.
    van Rossum HH
    Clin Chem Lab Med; 2019 May; 57(6):773-782. PubMed ID: 30307894
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Supersensitive PSA-analysis after radical prostatectomy: a powerful tool to reduce the time gap between surgery and evidence of biochemical failure.
    Haese A; Huland E; Graefen M; Huland H
    Anticancer Res; 1999; 19(4A):2641-4. PubMed ID: 10470210
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.